Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.
Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan.
NPJ Prim Care Respir Med. 2020 Mar 19;30(1):7. doi: 10.1038/s41533-020-0164-4.
The independent risk factors for death in patients admitted for asthma exacerbation have not been thoroughly investigated. This study aimed to investigate these independent risk factors and the relationship between mortality and the prescription patterns of anti-asthmatic medications in patients admitted for asthma exacerbation. Using a nested case-control design, we identified 267 cases (death after asthma admission) and 1035 controls (survival after asthma admission) from the Taiwan National Health Insurance Research Database (NHIRD) from 2001 to 2010. Conditional logistic regressions were used to estimate the odds ratios (ORs) with 95% confidence intervals (CIs). We identified the independent risk factors for death as the comorbidities of pneumonia (aOR 3.82, 95% CI 2.41-6.05), genitourinary disease (aOR 1.75, 95% CI 1.17-2.62), septicemia (aOR 4.26, 95% CI 2.61-6.94), diabetes mellitus (aOR 2.10, 95% CI 1.30-3.38), arrhythmia (aOR 2.00, 95% CI 1.14-3.50), and a history of asthmatic hospitalization (aOR 4.48, 95% CI 2.77-7.25). Moreover, the use of short-acting β-agonist (SABA) and the dosage of oral corticosteroids (OCSs) >70 mg prednisolone during previous hospitalization (all p < 0.05) and the dosage of OCSs ≥110 mg prednisolone/month (aOR 2.21, 95% CI 1.08-4.50) during outpatient treatment independently increased the risk of death. The inhaled corticosteroids (ICSs) ≥4 canisters/year (aOR 0.39, 95% CI 0.19-0.78) independently reduced the risk of death. Specific comorbidities, asthma severity, and prescription patterns of SABA, OCSs, and ICSs were independently associated with mortality in patients admitted for asthma exacerbation. These results can be utilized to help physicians identify asthmatic patients who are at a higher mortality risk and to refine the management of the condition.
因哮喘急性加重而住院的患者的死亡独立风险因素尚未得到充分研究。本研究旨在调查这些独立风险因素,以及哮喘急性加重住院患者的死亡率与抗哮喘药物处方模式之间的关系。我们使用巢式病例对照设计,从 2001 年至 2010 年从台湾全民健康保险研究数据库(NHIRD)中确定了 267 例病例(哮喘入院后死亡)和 1035 例对照(哮喘入院后存活)。使用条件逻辑回归估计优势比(OR)及其 95%置信区间(CI)。我们发现肺炎(OR 3.82,95%CI 2.41-6.05)、泌尿生殖系统疾病(OR 1.75,95%CI 1.17-2.62)、败血症(OR 4.26,95%CI 2.61-6.94)、糖尿病(OR 2.10,95%CI 1.30-3.38)、心律失常(OR 2.00,95%CI 1.14-3.50)和哮喘住院史(OR 4.48,95%CI 2.77-7.25)是死亡的独立风险因素。此外,在住院期间使用短效 β-激动剂(SABA)和口服皮质类固醇(OCS)剂量>70mg 泼尼松龙(均 p<0.05)以及门诊治疗期间 OCS 剂量≥110mg 泼尼松龙/月(OR 2.21,95%CI 1.08-4.50)独立增加了死亡风险。吸入皮质类固醇(ICS)剂量≥4 罐/年(OR 0.39,95%CI 0.19-0.78)独立降低了死亡风险。特定合并症、哮喘严重程度以及 SABA、OCS 和 ICS 的处方模式与哮喘急性加重住院患者的死亡率相关。这些结果可用于帮助医生识别死亡率较高的哮喘患者,并改进对该疾病的管理。